

## REFERENCE LIST FOR THE BROCHURE: ELISIO™ HX, A NOVEL SHARP CUT-OFF DIALYZER



1. Kalantar-Zadeh K, et al. Slipping through the pores: hypoalbuminemia and albumin loss during hemodialysis. *Int J Nephrol Renovasc Dis.* 2021
2. Dozio E, et al. Sarcopenia in chronic kidney disease: focus on advanced glycation end products as mediators and markers of oxidative stress. *Biomedicines.* 2021
3. Maduell F, et al. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. *J Am Soc Nephrol.* 2013
4. Maduell F, et al. ESHOL study reanalysis: All-cause mortality considered by competing risks and time-dependent covariates for renal transplantation. *Nefrologia.* 2016
5. Abe M, et al. High-performance dialyzers and mortality in maintenance hemodialysis patients. *Sci Rep.* 2021
6. Mc Causland FR, et al. C-reactive protein and risk of esrd: results from the trial to reduce cardiovascular events with aranesp therapy (treat). *Am J Kidney Dis.* 2016
7. Panichi V, et al. The RISCAVID study. *NDT.* 2008
8. Chang CH, et al. Elevation of interleukin-18 correlates with cardiovascular, cerebrovascular, and peripheral vascular events: a cohort study of hemodialysis patients. *Medicine.* 2015
9. Liabeuf S, et al. Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. *KI.* 2012
10. Foster MC, et al. CRIC Study. *AJKD.* 2016
11. Scarpioni R, et al. Dialysis-related amyloidosis: challenges and solutions. *Int J Nephrol Renovasc Dis.* 2016
12. Cohen G. Immune dysfunction in uremia 2020. *Toxins.* 2020
13. Cohen G, et al. Immunoglobulin light chains modulate polymorphonuclear leucocyte apoptosis. *EJCI.* 2003
14. Fraser SDS, et al. The association of serum free light chains with mortality and progression to end-stage renal disease in chronic kidney disease: systematic review and individual patient data meta-analysis. *Mayo Clinic proceedings.* 2017
15. Desjardins L, et al. Association between free light chain levels, and disease progression and mortality in chronic kidney disease. *Toxins.* 2013
16. Lorenz G, et al. Mortality prediction in stable hemodialysis patients is refined by YKL-40, a 40-kDa glycoprotein associated with inflammation. *KI.* 2018

17. Vega A, et al. The new marker YKL-40, a molecule related to inflammation, is associated with cardiovascular events in stable haemodialysis patients. Clin. Kidney J. 2020
18. Kreiter, et al. eXcorLab. 2021. Data on file. [To access the study abstract please click here.](#)
19. Martinez Miguel et al. Abstract presented at ERA 2022.  
[https://academic.oup.com/ndt/article/37/Supplement\\_3/gfac077.012/6577626?searchresult=1](https://academic.oup.com/ndt/article/37/Supplement_3/gfac077.012/6577626?searchresult=1)
20. Owen WF, et al. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med. 1993
21. <[https://www.dopps.org/DPM/Files/meanalbumingdl\\_c\\_overallTAB.htm](https://www.dopps.org/DPM/Files/meanalbumingdl_c_overallTAB.htm). . 2020>
22. Maduell F, et al. Medium cut-off dialyzer versus eight hemodiafiltration dialyzers: comparison using a global removal score. Blood purif. 2019
23. van Gelder MK, et al. Albumin handling in different hemodialysis modalities. Nephrol Dial Transplant. 2018
24. Peters SA, et al. Haemodiafiltration and mortality in end-stage kidney disease patients: a pooled individual participant data analysis from four randomized controlled trials. NDT. 2016
25. Wolley M, et al. Exploring the clinical relevance of providing increased removal of large middle molecules. CJASN. 2018
26. Florens N, et al. Expanded haemodialysis: news from the field. NDT. 2018
27. Keoleian, et al. Life cycle material data update for GREET Model. University of Michigan. 2012.